Codiak BioSciences Revenue and Competitors
Estimated Revenue & Valuation
- Codiak BioSciences's estimated annual revenue is currently $20.5M per year.
- Codiak BioSciences received $76.5M in venture funding in November 2017.
- Codiak BioSciences's estimated revenue per employee is $310,000
- Codiak BioSciences's total funding is $234.9M.
- Codiak BioSciences has 66 Employees.
- Codiak BioSciences grew their employee count by -39% last year.
Codiak BioSciences Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Codiak BioSciences?
Codiak is the leader in the emerging field of exosome therapeutics, working to harness the power of this cellular messenger system to create potentially life-changing medicines. A venture-backed startup founded in 2015, Codiak has rapidly built a proprietary technology platform for exosome engineering and manufacturing that allows for precise targeting of important molecular pathways, opening the door to the development of therapies for cancer and other diseases. Led by an experienced and dedicated team, Codiak has at its foundation a positive and collaborative culture that is deeply rooted in cutting edge science and promotes opportunity for growth. Recent discoveries have transformed our understanding of the role of exosomes in the body. We now know that these natural, cell-derived vesicles can act as a potent and safe delivery system for multiple therapeutic payloads. Recognizing the enormous potential of exosomes, Codiak is applying leading-edge translational science and rigorous drug development to build a pipeline of candidates with broad utility and the capacity to address currently undruggable targets. While our initial focus is on oncology/immuno-oncology, this approach also offers significant potential in hematology, neurology and gene therapy and other therapy areas. At Codiak, we are working to create a major shift in the development of tomorrow's medicines through scientific ambition, remarkable ingenuity and deep passion for improving patients lives. Located in the heart of Boston's biotechnology hub in Cambridge, Massachusetts, we are advancing a bold vision by tapping into the unique talents of a varied pool of individuals who together are achieving truly exceptional work. Come Join Us.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Codiak BioSciences News
Codiak BioSciences (NASDAQ:CDAK) Rating Lowered to Hold at Zacks Investment Research. Posted by admin on Apr 27th, 2022.
By Josh Beckerman. Codiak BioSciences Inc. shares rose 4% to $4.05 as it presented preclinical data that "demonstrate the potential for a...
Codiak is a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics, a new class of medicines with the...
CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today the pricing of its underwritten publ ...
Takara Bio Company, Illumina Inc, Thermo Fisher Scientific Inc, Codiak BioSciences, Evox Therapeutics Limited, HansaBioMed Life Sciences, ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Codiak BioSciences Funding
|2015-11-18||$80.0M||Undisclosed||ARCH Venture Partners||Article|
|2016-01-27||$61.0M||B||ARCH Venture Partners||Article|